{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:52:10Z","timestamp":1791388330457,"version":"4.3.3"},"reference-count":10,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"DOI":"10.1001\/jamadermatol.2026.3855","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:31Z","timestamp":1791385231000},"source":"Crossref","is-referenced-by-count":0,"title":["Improved Risk Stratification in Advanced Mycosis Fungoides and S\u00e9zary Syndrome"],"prefix":"10.1001","author":[{"given":"Laura B.","family":"Pincus","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"5","key":"ded260010r1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"issue":"14","key":"ded260010r2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood.2025029628","article-title":"A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.","volume":"146","author":"Scarisbrick","year":"2025","journal-title":"Blood"},{"issue":"32","key":"ded260010r3","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model.","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"ded260010r4","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2026.3856","article-title":"Cutaneous Lymphoma International Prognostic Index and risk stratification in advanced mycosis fungoides and s\u00e9zary syndrome.","author":"Roccuzzo","year":"2026","journal-title":"JAMA Dermatol"},{"issue":"7","key":"ded260010r5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1182\/blood.2020008241","article-title":"Integrating novel agents into the treatment of advanced mycosis fungoides and S\u00e9zary syndrome.","volume":"141","author":"Khodadoust","year":"2023","journal-title":"Blood"},{"issue":"10094","key":"ded260010r6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ded260010r7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis.","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"ded260010r8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamadermatol.2020.4901","article-title":"Brentuximab vedotin for relapsed or refractory S\u00e9zary syndrome.","volume":"157","author":"Lewis","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"9","key":"ded260010r9","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"ded260010r10","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1111\/jdv.17523","article-title":"Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.","volume":"35","author":"Cowan","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2854946\/jamadermatology_pincus_2026_ed_260010_1791216046.516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:31Z","timestamp":1791385231000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2854946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.3855","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}